DelveInsight’s, “ Idiopathic Pulmonary Fibrosis Pipeline Insights 2025 ” report provides comprehensive insights about 80+ ...

Kristy Smith says in June she was diagnosed with idiopathic pulmonary fibrosis which caused scarring on the lungs and makes ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal lung disease characterised by the accumulation of scar ...

Christopher Kennedy didn't think anything was wrong. Soon, doctors were telling him a double lung transplant was his only ...

BEACON-IPF close out activities continuePreviously announced workforce and operational realignment largely completePhase 1 ...

Our 2024 Year-in-Review: Idiopathic Pulmonary Fibrosis highlights breakthroughs, clinical trial insights, and emerging therapies shaping the future of IPF management.

Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.

Panelists discuss how effective management of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) relies on early, accurate diagnosis and multidisciplinary collaboration ...

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely ...

The study found through multi-omics integration analysis that rheumatoid arthritis is a causal factor of idiopathic pulmonary ...

In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with ...